Conditions: Metastatic Castration-Resistant Prostate Cancer
Keywords: MDV3100 Xtandi Abiraterone Metastatic Castration-Resistant Prostate Cancer Enzalutamide
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 215
Healthy volunteers: no

Brief summary:
The objective of this study was to evaluate the efficacy and safety of enzalutamide treatment in patients with progressive metastatic castration-resistant prostate cancer previously treated with abiraterone acetate.

Detailed description:

Arms:
arm 1: Participants received 160 mg of enzalutamide orally once daily until they experienced an adverse event, disease progression, started new anti-cancer therapy, withdrew consent, or other protocol-specified criteria.

Interventions: intervention 1: Enzalutamide
Intervention descriptions: intervention 1: Participants received 160 mg of enzalutamide (soft capsules) orally once daily.

Protocol document: